Vaxart, Inc. (VXRT)
0.5005
-0.01
(-2.82%)
USD |
OTCM |
Aug 24, 16:00
Vaxart Price to Book Value : 1.476 for Aug. 24, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 1.476 |
| August 21, 2026 | 1.518 |
| August 20, 2026 | 1.532 |
| August 19, 2026 | 1.467 |
| August 18, 2026 | 1.460 |
| August 17, 2026 | 1.456 |
| August 14, 2026 | 1.602 |
| August 13, 2026 | 1.651 |
| August 12, 2026 | 1.650 |
| August 11, 2026 | 1.643 |
| August 10, 2026 | 1.695 |
| August 07, 2026 | 1.623 |
| August 06, 2026 | 1.680 |
| August 05, 2026 | 1.738 |
| August 04, 2026 | 1.769 |
| August 03, 2026 | 1.740 |
| July 31, 2026 | 1.592 |
| July 30, 2026 | 1.554 |
| July 29, 2026 | 1.423 |
| July 28, 2026 | 1.421 |
| July 27, 2026 | 1.327 |
| July 24, 2026 | 1.459 |
| July 23, 2026 | 1.472 |
| July 22, 2026 | 1.409 |
| July 21, 2026 | 1.484 |
| Date | Value |
|---|---|
| July 20, 2026 | 1.474 |
| July 17, 2026 | 1.518 |
| July 16, 2026 | 1.518 |
| July 15, 2026 | 1.562 |
| July 14, 2026 | 1.621 |
| July 13, 2026 | 1.598 |
| July 10, 2026 | 1.610 |
| July 09, 2026 | 1.614 |
| July 08, 2026 | 1.622 |
| July 07, 2026 | 1.622 |
| July 06, 2026 | 1.819 |
| July 02, 2026 | 1.887 |
| July 01, 2026 | 1.792 |
| June 30, 2026 | 1.784 |
| June 29, 2026 | 1.467 |
| June 26, 2026 | 1.384 |
| June 25, 2026 | 1.300 |
| June 24, 2026 | 1.334 |
| June 23, 2026 | 1.331 |
| June 22, 2026 | 1.372 |
| June 18, 2026 | 1.413 |
| June 17, 2026 | 1.459 |
| June 16, 2026 | 1.443 |
| June 15, 2026 | 1.475 |
| June 12, 2026 | 1.436 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Agenus, Inc. | -- |
| Amgen, Inc. | 20.47 |
| Anika Therapeutics, Inc. | 2.098 |
| BioCryst Pharmaceuticals, Inc. | -- |
| Imunon, Inc. | 1.804 |
Price to Book Value Related Metrics
| PE Ratio | 3.148 |
| PS Ratio | 0.491 |
| Price to Free Cash Flow | 3.575 |
| Price | 0.5005 |
| Earnings Yield | 31.77% |
| Market Cap | 121.54M |
| Operating PE Ratio | 3.013 |
| Normalized PE Ratio | 3.148 |